vTv Therapeutics Inc. (NASDAQ:VTVT) major shareholder Ronald O. Perelman purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The stock was bought at an average price of $4.97 per share, with a total value of $49,700.00. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) traded up 0.41% during mid-day trading on Wednesday, hitting $4.95. The company had a trading volume of 38,234 shares. The firm’s market capitalization is $47.98 million. vTv Therapeutics Inc. has a 52-week low of $3.57 and a 52-week high of $7.50. The firm has a 50-day moving average price of $4.59 and a 200 day moving average price of $5.26.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.02. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.19 million. Analysts expect that vTv Therapeutics Inc. will post ($1.06) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “vTv Therapeutics Inc. (VTVT) Major Shareholder Ronald O. Perelman Purchases 10,000 Shares” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/16/vtv-therapeutics-inc-vtvt-major-shareholder-ronald-o-perelman-purchases-10000-shares.html.

Several institutional investors have recently bought and sold shares of the company. Sphera Funds Management LTD. boosted its position in shares of vTv Therapeutics by 50.0% in the first quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biotechnology company’s stock valued at $1,965,000 after buying an additional 100,000 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of vTv Therapeutics by 62.7% in the second quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock valued at $1,313,000 after buying an additional 101,850 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new position in shares of vTv Therapeutics during the first quarter valued at approximately $917,000. State Street Corp boosted its position in shares of vTv Therapeutics by 2.1% in the second quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after buying an additional 1,976 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of vTv Therapeutics by 4.8% in the first quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock valued at $418,000 after buying an additional 2,900 shares in the last quarter. 11.16% of the stock is owned by hedge funds and other institutional investors.

VTVT has been the subject of several recent analyst reports. Zacks Investment Research lowered vTv Therapeutics from a “buy” rating to a “sell” rating in a research report on Wednesday, July 5th. HC Wainwright set a $13.00 target price on vTv Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 4th. Finally, Canaccord Genuity restated a “buy” rating and set a $15.00 target price on shares of vTv Therapeutics in a research report on Friday, August 4th. Five investment analysts have rated the stock with a buy rating, vTv Therapeutics presently has an average rating of “Buy” and a consensus target price of $14.15.

About vTv Therapeutics

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.